This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.
Histologically confirmed diffuse large B-cell lymphoma (DLBCL).
Have received ≥1 line of systemic antitumor therapy.
At least one bi-dimensionally measurable lesion.
Expected survival of at least 3 months.
Central nervous system lymphoma involvement.
Primary mediastinal (thymus) large B-cell lymphoma.
Patients who have only one prior line therapy and are candidates for stem cell transplantation.
A history of immunodeficiency.